Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


Delayed Quote. Delayed Swiss Exchange - 01/22 11:30:30 am
85.93 CHF   +0.37%
01/22NOVARTIS AG : Barclays keeps a Sell rating
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Genmab Announces Enapotamab Vedotin Update

11/25/2020 | 09:56am EST

Copenhagen - Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin.

While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab's stringent criteria for proof-of-concept.

'We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward. This decision will allow us to focus more of our resources and energy on other programs in our robust next-generation antibody therapeutics pipeline,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About Enapotamab Vedotin

Enapotamab vedotin is an AXL targeted Antibody-Drug Conjugate (ADC) in which the monoclonal antibody is conjugated to the antimitotic drug monomethyl auristatin E. AXL is a signaling molecule overexpressed in several hematologic and solid malignancies. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. Enapotamab vedotin is fully owned by Genmab and the drug linker technology used for enapotamab vedotin was licensed from Seagen Inc.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.


Marisol Peron

Tel: +1 609 524 0065

Email: mmp@genmab.com

This Company Announcement contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
GENMAB A/S 0.11% 2643 Delayed Quote.7.31%
NOVARTIS AG 0.37% 85.93 Delayed Quote.2.73%
All news about NOVARTIS AG
01/22NOVARTIS AG : Barclays keeps a Sell rating
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
01/20NOVARTIS AG : Credit Suisse reiterates its Neutral rating
01/20NOVARTIS AG : Jefferies keeps its Buy rating
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
01/19Novartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
01/19Novartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
01/19GSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
More news
Financials (USD)
Sales 2020 49 185 M - -
Net income 2020 8 364 M - -
Net Debt 2020 20 185 M - -
P/E ratio 2020 26,4x
Yield 2020 3,26%
Capitalization 221 B 221 B -
EV / Sales 2020 4,90x
EV / Sales 2021 4,49x
Nbr of Employees 110 000
Free-Float 86,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,54 $
Last Close Price 97,04 $
Spread / Highest target 53,4%
Spread / Average Target 12,9%
Spread / Lowest Target -7,00%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.73%220 726
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720